We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nine construction companies have registered their interest in bidding for a
Bt950-million contract to build a pharmaceutical plant to produce anti-AIDS
medicines, the Acting Managing Director of the Government Pharmaceutical Organization
(GPO), Wanchai Subhachaturus, told TNA.
Mylan Laboratories' rocky road toward acquiring King Pharmaceuticals has taken
two more turns that could complicate a deal already mired in controversy.
Officials at the FDA asked Canadian regulators to refrain from suspending the
use of the hyperactivity drug Adderall XR, because the FDA could not handle
another "drug safety crisis," according to Sen. Charles Grassley.
Cytel Software, a leading provider of software and services for optimized clinical
trial design and analysis, has completed a round of financing led by Merck Capital
Ventures.
WellGen, a biotechnology company using nutrigenomics to develop proprietary
wellness products, has signed a research contract and licensing agreement with
HMGene, a company focused on the genetics of obesity.
Gufic Biosciences has started discussions with potential investors, offering
them close to 10 percent equity in the company, reports Business Standard.
Emergent Technologies has formed a new biotech company, Auxano Biologics to
commercialize patented technology utilizing Substance P for wound healing applications
developed by Ted Reid, Chris Murphy and Mark Mannis.
Merck and GlaxoSmithKline (GSK) have settled their competing intellectual property
claims related to their human papillomavirus (HPV) vaccine candidates.
The Senate Health, Education, Labor, and Pensions (HELP) Committee sent a letter
to President Bush requesting he nominate a permanent FDA commissioner "as
soon as possible" and promising the president a prompt hearing on such
a nominee.
HHS Secretary Michael Leavitt has called for eliminating wasteful
spending on Medicaid, including by changing the way the government pays for
prescription drugs under the program.